C4 Therapeutics Unveils Promising Data on CFT1946 at ESMO 2024
![C4 Therapeutics Unveils Promising Data on CFT1946 at ESMO 2024](https://investorshangout.com/images/blog/ihnews-C4%20Therapeutics%20Unveils%20Promising%20Data%20on%20CFT1946%20at%20ESMO%202024.jpg)
C4 Therapeutics Presents Insights on CFT1946 at ESMO 2024
Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity
Investor Webcast Scheduled for September 13, 2024
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company focused on targeted protein degradation, announced exciting developments surrounding their Phase 1 clinical trial of CFT1946. This novel BiDAC™ degrader targets mutant BRAF V600 solid tumors. In conjunction with the European Society for Medical Oncology (ESMO) Congress 2024, important clinical data reflecting favorable safety and anti-tumor activity was made public.
The abstract, with data up to April 12, 2024, indicates promising results. An oral presentation will take place on September 13, 2024, and will include details from 36 patients regarding their demographics, safety measures, pharmacokinetics, pharmacodynamics, and anti-tumor activities assessed by RECIST 1.1 criteria.
Details of the ESMO 2024 Presentation
Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BiDAC™ Degrader in Mutant BRAF V600 Solid Tumors
Presentation Date and Time: September 13, 2024, 4:10 pm CEST (10:10 am ET)
Final Publication Number: 612O
Session Category: Proffered paper session 1
Session Title: Developmental therapeutics
Location: Santander Auditorium – Hall 5
Presenter: Maria Vieito, M.D., MSc (Barcelona, Spain)
Webcast for Analysts and Investors
C4T will conduct a webcast on September 13, 2024, at 12:00 pm ET to discuss the findings in detail. Participation in the webcast can be accessed via the company’s 'Events & Presentations' page on their official website. A recorded version of the webcast will be available afterward.
About C4 Therapeutics
C4 Therapeutics (C4T), a company listed on Nasdaq (CCCC), is at the forefront of bioscience, dedicated to bringing innovative, targeted therapies to market. They utilize their TORPEDO® platform to effectively strategize and enhance small-molecule medications for hard-to-treat conditions. Their proprietary medicine aims to exploit the body's natural protein recycling mechanisms to efficiently degrade harmful proteins, thus offering hope for challenging health issues like drug resistance.
Understanding CFT1946
CFT1946 is a breakthrough orally bioavailable BiDAC™ degrader that showcases strong selectivity for BRAF V600X mutations. Early preclinical findings demonstrate its effectiveness both in vivo and in vitro under various settings, especially in conditions driven by BRAF V600E mutations and resistant to standard BRAF inhibitors. This Phase 1 dose escalation study includes multiple solid tumor types – notably colorectal cancer, melanoma, and non-small cell lung cancer. Further trial details can be found in the clinical trial registry.
Frequently Asked Questions
What is C4 Therapeutics known for?
C4 Therapeutics is renowned for its innovations in targeted protein degradation science, focusing on developing therapies to treat difficult diseases.
What is CFT1946?
CFT1946 is an investigational medication that targets BRAF V600X mutations using BiDAC™ technology, showing promise in treating various solid tumors.
When will the ESMO Congress 2024 take place?
The ESMO Congress 2024 is scheduled from September 13 to 17, 2024.
How can I view the presentation from C4T?
You can view the oral presentation during the ESMO Congress directly through their official event channels or the C4T website.
Where can I get more information about the trials?
Detailed information regarding clinical trials, including CFT1946, can be accessed at www.clinicaltrials.gov.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please please contact us for corrections.
Related Articles
- HUTCHMED to Showcase Innovative Studies at Global Conferences
- E7386 Clinical Results and Promising Anticancer Collaboration
- Intel's Strategic Reversal: Challenges and Future Paths
- Toshiba Launches Innovative Masterstroke Series at IFA 2024
- UK Job Market Slows, Could Prompt Further Rate Cuts Soon
- Norfolk Southern Faces Leadership Scrutiny Over Allegations
- Westgold Resources Achieves Significant Milestone with ASX 200 Inclusion
- MacroGenics to Present Key Phase 2 Data at Upcoming Congress
- NOVONIX Engages Investors at Upcoming Investment Conference
- Alimentation Couche-Tard Emphasizes Value in Proposed Merger
Recent Articles
- Ultimovacs' New Findings on UV1 Vaccine for Mesothelioma
- Asian Markets React to Economic Indicators Amid Selloff
- Diverse Perspectives on Bond Market and Fed's Rate Decisions
- Westpac Welcomes Anthony Miller as New CEO
- Resecurity and Mannai Trading Team Up for Cybersecurity Growth
- Understanding Bitcoin Halvings: Impact on Future Investments
- Reforming Capital Gains Tax: A Path to Economic Growth
- Explore the Latest C3.ai Investigation by Prominent Law Firm
- Investors Take Action: Verve Therapeutics Faces Class Lawsuit
- Potential Lead Plaintiff Opportunity for ZoomInfo Investors
- Xiao-I Corporation's IPO: Understanding the Investor Landscape
- Investigation Launched for Lions Gate Entertainment Investors
- Investors Invited to Join Class Action Against GitLab Inc.
- Couche-Tard Expresses Interest in Seven & i Acquisition
- Norfolk Southern Board Investigates CEO Regarding Allegations
- Expert Analysis Indicates Possible Major Bitcoin Rally Ahead
- Bending Spoons Plans Significant Workforce Reduction at WeTransfer
- Assessing the Risks of Investing in Trump Media Stock
- Selecting the Ideal AI Chip Stock for Your Portfolio
- Crypto Market Recovery Insights from Chris Burniske
- Top Performing Mid-Cap Stocks: Insights for Investors
- Amivantamab and Lazertinib Advance Lung Cancer Survival Rates
- ICEYE Partners with Greece for Advanced SAR Satellite Solutions
- ICEYE Partners with ESA for Greek Satellite Initiative
- Significant Phase II Breakthrough for Akeso's Ivonescimab in NSCLC
- Market Insights: Uncovering S&P 500 Trends and Strategies
- The Shocking Story of Financial Betrayal and Trust Issues
- Latest Insights on RYBREVANT® and LAZCLUZE™ in Lung Cancer Treatment
- Significant Stock Drops: Which Large Caps Took a Hit?
- Walgreens Boots Alliance Faces Class Action Amid Legal Challenges
- Exploring IBM's Transformation and Future Growth Trajectory
- Top Large-Cap Stocks of August: Winners to Consider in 2024
- Ensuring FINRA Compliance in the Cloud with AdvisorVault
- Investing Insights: Is It Time to Consider SoFi Technologies?
- DirecTV Takes Legal Stand Against Disney's Contract Practices
- Understanding Nvidia's Recent $50 Billion Buyback Decision
- Nvidia's Recent Market Slide: Analyzing the Trends
- Breakthrough Data on Ivonescimab for NSCLC Treatment
- Debate Highlights: Kamala Harris and Donald Trump Face Off
- Kendrick Lamar Set to Rock Super Bowl LIX Halftime Show in 2025
- Janet Yellen's Optimism for U.S. Economy: Impact on Bitcoin
- Federal Support for 32 New Homes: A Positive Housing Shift
- Nvidia's Future: Doubling Revenue and Stock Amid Market Challenges
- Exploring Amazon's Investment Potential: Buy, Sell, or Hold?
- Join the CAE Inc. Class Action: Important Investor Insights
- Investors Invited to Participate in CrowdStrike Lawsuit Action
- Israel's Stock Market Sees Declines Led by Key Sectors
- Understanding the Federal Reserve's Timing on Interest Rates
- Cathie Wood's Bitcoin Predictions: Insight and Outlook
- Unlocking Potential: Top Stocks to Watch in Tech and Fintech